Literature DB >> 28009758

Evidence-Based Surveillance Imaging Schedule After Liver Transplantation for Hepatocellular Carcinoma Recurrence.

Dan Liu1, Albert C Y Chan, Daniel Y T Fong, Chung-Mau Lo, Pek-Lan Khong.   

Abstract

BACKGROUND: There is presently no evidence-based recommendation for surveillance of recurrent hepatocellular carcinoma after liver transplantation (LT). We aim to evaluate and develop evidence-based alternate surveillance imaging schedules for post-LT hepatocellular carcinoma patients.
METHODS: Imaging and pathologic reports for consecutive post-LT patients followed up by regular surveillance imaging from a single institution's prospective database were evaluated with institutional review board approval. Outcome variable was time to diagnosis of first recurrence post-LT by surveillance imaging. Recurrence-free survival times from alternative surveillance schedules were compared with the existing schedule (every 3 months) using a parametric frailty model. Expected delay (EpD) in diagnosis compared to the existing schedule was also computed for the alternate surveillance schedules. A P value less than 0.05 was considered to indicate a significant difference.
RESULTS: One hundred twenty-five patients (108 men; 59.4 ± 16.6 years) underwent 1953 computed tomography and 255 magnetic resonance imaging scans. Recurrence-free survival time was not significantly different in the first 5 years after LT when the imaging interval was extended from current every 3 months to every 6 months (P = 0.786, EpD = 55 days). This alternative schedule incurred 10 (50.0%) fewer surveillance scans than the 20 in the original schedule, and a corresponding reduction in radiation dose (if involved) and cost during the 5-year follow-up period.
CONCLUSIONS: In conclusion, modeled alternative surveillance schedules have the potential to reduce the frequency of scans without compromising surveillance benefits.

Entities:  

Mesh:

Year:  2017        PMID: 28009758     DOI: 10.1097/TP.0000000000001513

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

2.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

Review 3.  Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.

Authors:  Naga Swetha Samji; Rajanshu Verma; Krishna Chaitanya Keri; Ashwani K Singal; Aijaz Ahmed; Mary Rinella; David Bernstein; Manal F Abdelmalek; Sanjaya K Satapathy
Journal:  Dig Dis Sci       Date:  2019-07-16       Impact factor: 3.199

4.  Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation.

Authors:  Wenwu Liu; Yun Zheng; Ruhai Zou; Jingxian Shen; Wei He; Zhiwen Yang; Yuanping Zhang; Binkui Li; Yunfei Yuan
Journal:  BMC Cancer       Date:  2018-11-29       Impact factor: 4.430

5.  Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment.

Authors:  Ka Eun Kim; Dong Hyun Sinn; Moon Seok Choi; Honsoul Kim
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

Review 6.  The management of post-transplantation recurrence of hepatocellular carcinoma.

Authors:  Luckshi Rajendran; Tommy Ivanics; Marco Paw Claasen; Hala Muaddi; Gonzalo Sapisochin
Journal:  Clin Mol Hepatol       Date:  2021-10-05

7.  Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Jae H Yoon; Young J Goo; Chae-Jun Lim; Sung K Choi; Sung B Cho; Sang S Shin; Chung H Jun
Journal:  World J Gastroenterol       Date:  2020-08-28       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.